How Exact Sciences Stock Has Been Performing Exact Sciences (EXAS) has drawn investor attention after a strong run over the past 3 months, with the move putting more focus on how its cancer screening ...

Why Abbott’s Price Target Just Nudged Higher Abbott Laboratories has seen its implied fair value estimate edge to about ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...

The following segment was excerpted from the Alger Mid Cap Focus Fund Q4 2025 Commentary.Class A shares of the Alger Mid Cap ...

Exact SciencesEXAS stock crashed to a three-year low Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test. The company already developed a blood-based ...

In the assessment of 12-month price targets, analysts unveil insights for Exact Sciences, presenting an average target of $91 ...

On Nov. 20, Exact announced a definitive agreement to be acquired by Abbott Laboratories with an expected close in the second quarter of 2026. Exact shareholders will receive $105 per common share, ...

Kevin Conroy, Chairman and CEO, highlighted Exact Sciences' progress in 2024, including delivering over 4.6 million test results, achieving 11% core revenue growth, and increasing EBITDA by 48%. He ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® ...